ABVC BioPharma Receives $3.175 Million Investment From The Lind Partners to Continue Clinical Trials

Posted: February 24, 2023 at 12:14 am

FREMONT, CA, Feb. 23, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – ABVC BioPharma, Inc. (NASDAQ: ABVC), a clinical stage biopharmaceutical company developing therapeutic solutions in oncology/hematology, CNS, and ophthalmology, today announced it has closed a funding agreement for gross proceeds of $3.175 million (the "Investment") with Lind Global Fund II, LP, an investment fund managed by The Lind Partners (together “Investor” or “Lind”), a New York-based institutional fund manager.

Read more here:
ABVC BioPharma Receives $3.175 Million Investment From The Lind Partners to Continue Clinical Trials

Related Posts